

2025

Catalog

promise
ADVANCED PROTEOMICS

SIL-mAbs

FOR TARGETED LC-MS QUANTIFICATION



Improve accuracy across your Mass Spectrometry workflows

www.promise-proteomics.com | contact@promise-proteomics.com

SIL-MONOCLONAL ANTIBODIES

PROMISE Proteomics is a pioneer and an expert in the development of Mass Spectrometry-based quantification methods and in the bioproduction of Stable-Isotope-Labelled (SIL) monoclonal Antibodies (mAbs).

Why use our SIL-mAbs ?

A SIL form of an analyte protein is widely regarded as the optimal internal standard¹ for absolute quantification of proteins using LC-MS.

SIL-mAbs correct bias (due to incomplete digestion, losses, adsorption, proteolysis, etc.) occurring during the preparation and analytical workflow. With SIL-mAbs, the accuracy and reproducibility of your quantification data is improved.


This product is useful for:

- Bioanalysis pharmacokinetics studies (clinical & non-clinical),
- Research & Discovery as well as pre-clinical & clinical Drug Development

Characteristics

- Full length recombinant monoclonal antibodies
- High isotopic incorporation (>98%) and purity (>95%)
- Labelling on Arg, Lys residues, $^{13}\text{C}^{15}\text{N}$ isotope
- Expression systems CHO or HEK

How to use our solutions?



Unlike the use of SIL-peptides, Promise's SIL-mAbs are processed along with the target analytes throughout the pre-analytical and LC-MS workflow thus improving robustness and quality of the quantitative data.

1. Todoroki, K. *et al.* (2020, février). Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates : A review of recent advances and future perspectives. *Journal of Pharmaceutical and Biomedical Analysis*, 179, 112991. <https://doi.org/10.1016/j.jpba.2019.112991>

OFF-THE-SHELF PRODUCTS

SIL-mAbs* are available to support your studies and clinical trials.

Your mAb of interest is not listed? Please contact our experts for custom bioproduction.

SIL-mAbs	REFERENCES	SIL-mAbs	REFERENCES
Abatacept	ORF90261	Golimumab	SIU05281
Adalimumab	HUU05211	Guselkumab	TRU05271
Aflibercept	AFF90271	Infliximab	REX08151
Alemtuzumab	ALZ10131	Inotuzumab	INZ13241
Avelumab	BAU05571	Ipilimumab	YEU05271
Belatacept	<i>upon request</i>	Ixekizumab	TAZ13261
Bevacizumab	AVZ10161	Mirikizumab	OMZ13191
Brentuximab	BRX08181	Natalizumab	TYZ13211
Cetuximab	ERX08221	Nivolumab	OPU08201
Concizumab	COZ13241	Obinutuzumab-Like	GAH92161
Crovalimab	PIZ10191	Ocrelizumab	OCZ10231
Daratumumab	DAU05201	Pembrolizumab	KEZ13331
Datopotamab	DAZ10161	Pertuzumab	PEZ10191
Dinutuximab	DIX08251	Polatuzumab	POZ10211
Dupilumab	DUU08301	Risankizumab	SKZ10121
Durvalumab	IMU05501	Rituximab	RIX08221
Eculizumab	SOZ11141	Sacituzumab	SAZ10141
Emicizumab-Like	HEH95561	Secukinumab	COU05201
Enfortumab	PAZ10201	Siltuximab	SYX08151
Epcoritamab	EPZ10171	Tocilizumab	ACZ10241
Etanercept	ENF90251	Trastuzumab	HEZ10231
Frexalimab	FRZ10201	Ustekinumab	STU05261
		Vedolizumab	ENZ10211

**for Research Use Only*



✉ contact@promise-proteomics.com

REFERENCES

Peer reviewed publications using our SIL-mAbs

- **Mayo Clinic**

Ladwig, P. *et al.* (2024). Infliximab Therapeutic monitoring by tryptic peptide LC-MS/MS method improvements lead to improved accuracy with decreased imprecision and turnaround time. *Journal of Mass Spectrometry and Advances in the Clinical Lab*, 32, 24-30. <https://doi.org/10.1016/j.jmsacl.2024.01.007>

- **Hospices Civils de Lyon**

Millet, A. *et al.* (2021). Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa. *Biomedicines*, 9(6), 621. <https://doi.org/10.3390/biomedicines9060621>

- **Hospices Civils de Lyon**

Millet, A. *et al.* (2019). Determination of Cetuximab in Plasma by Liquid Chromatography–High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled ¹³C,¹⁵N-Cetuximab Internal Standard. *Therapeutic Drug Monitoring*, 41(4), 467-475. <https://doi.org/10.1097/ftd.0000000000000613>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2018). Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry. *Therapeutic Drug Monitoring*, 40(4), 417-424. <https://doi.org/10.1097/ftd.0000000000000514>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2016). Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry : towards a standardization of the methods ? *Analytical and Bioanalytical Chemistry*, 409(5), 1195-1205. <https://doi.org/10.1007/s00216-016-0045-4>

- **University Medical Center Utrecht**

el Amrani, M. *et al.* (2016). Quantification of active infliximab in human serum with liquid chromatography–tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard : A target-based, sensitive and cost-effective method. *Journal of Chromatography A*, 1454, 42-48. <https://doi.org/10.1016/j.chroma.2016.05.070>

PROMISE Proteomics S.A.S.

7, parvis Louis Néel • BHT 52 A • CS 20050 - 38040 Grenoble Cedex 9 • FRANCE

Phone: +33 438 023 650 | RCS Grenoble B 433 546 504